DELRAY BEACH, Fla., May 31, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it has added international healthcare and business development executive Benedikt von Braunmühl to its Board of Advisors.

Von Braunmühl is currently Chairman of the Board of Directors of PathoQuest, a next generation molecular diagnostics company with a unique approach in infectious diseases diagnostics. In addition, he acts as advisor of the healthcare practice group at Clairfield International, a mergers and acquisitions advisory firm for global mid-market transactions with 39 offices in 23 countries. He has held several high-profile healthcare consulting and advisory roles for companies across the globe supporting geographic expansion, business development, and mergers and acquisitions projects. Von Braunmühl previously was Senior Vice President - Global Commercial Operations of Qiagen NV, a leading European biotechnology company active in molecular diagnostics and life science markets.

“We are honored to add Benedikt to our Board of Advisors to raise awareness of our product offerings and our technical and scientific expertise among potential partners,” said William J. Caragol, Chairman and CEO of PositiveID. “We believe his strategic insights and broad industry relationships, which align closely with our business, will be valuable in helping us reach the next stage in our growth.”

Mr. von Braunmühl started his 25-year healthcare career at AstaMedica and has held various marketing and sales positions in the healthcare industry as well as in investment banking. He holds a Bachelor Degree in Business Administration from the Graduate School of Business Administration in Zurich, Switzerland.

About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit, or connect with PositiveID on Twitter, Facebook or LinkedIn.

Statements about PositiveID's future expectations, including the likelihood that Mr. von Braunmühl will assist the Company’s efforts to commercialize Firefly Dx to detect Zika and other pathogens; the likelihood that his strategic insights and broad industry relationships, which align closely with our business, will be valuable in helping us reach the next stage in our growth; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market, as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on May 16, 2016, November 12, 2015, and August 13, 2015, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: Contacts:
PositiveID Corporation
Allison Tomek
(561) 805-8044

RedChip Companies
Jon Cunningham
(407) 644-4256